<DOC>
	<DOCNO>NCT00693446</DOCNO>
	<brief_summary>Experience tacrolimus pancreas transplantation become standard immunosuppression almost pancreas center world . Several center show good result simultaneous pancreas-kidney ( SPK ) transplant recipient receive antithymocyte globulin induction maintenance immunosuppression consist calcineurin inhibitor mycophenolate mofetil without corticosteroid . The use sirolimus SPK transplant patient moment study , good result , association tacrolimus cyclospsorine ( CsA ) . In renal transplantation , also evidence sirolimus ( Rapamune ) potent immunosuppressant significantly reduce incidence acute rejection give CsA , effective base therapy post-induction period . Because Rapamune 's effectiveness different safety profile , might advantageous term reduce nephrotoxicity avoid completely calcineurin inhibitor without increase incidence acute rejection . To explore , follow study design assess use SRL versus TAC , treatment group include rATG plus MMF 3-month course steroid de novo simultaneous pancreas-kidney transplant recipient .</brief_summary>
	<brief_title>A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids</brief_title>
	<detailed_description>The main objective compare renal pancreas graft survival 12 month simultaneous pancreas-kidney transplantation patient receive either regimen combine sirolimus ( SRL ) plus mycophenolate mofetil ( MMF ) follow antibody induction ( rATG ) regimen combine tacrolimus ( TAC ) plus mycophenolate mofetil follow antibody induction ( rATG ) . In regimens corticosteroid ( CS ) withdraw three month transplantation . In addition , two treatment group compare acute rejection , renal pancreas function patient survival transplantation 12 month total period 5 year follow-up .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Recipient age ≥ 18 ≤ 60 year . Patients receive first cadaveric simultaneous pancreaskidney transplant insulindependent diabetes associate endstage renal disease . Women childbearing potential must negative serum pregnancy test agree use medically acceptable method contraception throughout treatment period 3 month follow discontinuation . Signed date informed consent . Donor age ≤ 15 year ≥ 60 year . Evidence active systemic localize major infection . Evidence infiltrate , cavitation , consolidation chest xray . Use investigational drug treatment ( particular immunosuppressive drug ) 4 week prior enrollment study 12month treatment phase . History malignancy ( exception adequately treat localized squamous cell basal cell carcinoma , without recurrence within 5 year enrolment study ) . Graft live donor . Double renal graft . Pregnancy . Known hypersensitivity sirolimus derivative tacrolimus . Known hypersensitivity rabbit 's protein . Multiple organ transplant recipients previously transplant organ kidney . Treatment cisapride ( PrépulsidÒ ) , pimozide ( OrapÒ ) , ketoconazole ( NizoralÒ ) , fluconazole ( TriflucanÒ ) millepertuis ( ProcalmilÒ , Arkogélules MillepertuisÒ ) , discontinue within 24 hour prior transplant . Total white blood cell count ≤ 2 x 109/L platelet count ≤ 70.000/mm3 baseline . Patients evidence active histological biological hepatic disease six month period transplantation . HIV positive recipient . Nonheart beat donor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pancreas-kidney allograft</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>Pancreas-kidney allograft recipient</keyword>
</DOC>